- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.210 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| 02.10. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.09. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth | 265 | ACCESS Newswire | Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)... ► Artikel lesen | |
| 27.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference | 420 | ACCESS Newswire | Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 12.08. | CNS Pharmaceuticals GAAP EPS of -$0.37 misses by $0.13 | 6 | Seeking Alpha | ||
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation | 537 | ACCESS Newswire | Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline... ► Artikel lesen | |
| 12.08. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 02.07. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 08.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment | 361 | ACCESS Newswire | Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative... ► Artikel lesen | |
| 20.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress | 446 | ACCESS Newswire | Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals reports Q1 results | 2 | Seeking Alpha | ||
| 14.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress | 340 | ACCESS Newswire | Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.05. | What's Going On With CNS Pharmaceuticals Stock On Wednesday? | 4 | Benzinga.com | ||
| 04.05. | CNS Pharmaceuticals Stock Surges 263% On Private Placement | 7 | RTTNews | ||
| 04.05. | CNS Pharmaceuticals raises $22.5 million in private placement | 3 | Investing.com | ||
| 04.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing | 622 | ACCESS Newswire | The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to... ► Artikel lesen | |
| 04.05. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | CNS Pharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 11.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline | 624 | ACCESS Newswire | Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,120 | +6,85 % | Biofrontera AG: FDA-Erfolg - diese Frage bleibt offen | ||
| DEFENCE THERAPEUTICS | 0,236 | -7,81 % | Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates | Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| TRAWS PHARMA | 0,440 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CURIS | 0,650 | +8,55 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 2,725 | +0,18 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 0,975 | +5,41 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| NEOVACS | 0,107 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 0,790 | +0,52 % | Alaunos Therapeutics, Inc. - 8-K, Current Report | ||
| MARKER THERAPEUTICS | 0,695 | -10,90 % | H.C. Wainwright reiterates Marker Therapeutics stock rating at buy | ||
| AINOS | 1,220 | +0,83 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| MATINAS BIOPHARMA | 0,054 | 0,00 % | XFRA 6LJ: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMATINA.BIOPHA. O.N.... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,475 | +1,72 % | Enveric receives U.S. patent allowance for psychiatric compounds | ||
| NEUPHORIA THERAPEUTICS | 3,360 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 1,180 | 0,00 % | SCINAI IMMUNOTHERAPEUTICS LTD: Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement | Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter... ► Artikel lesen | |
| CLEARMIND MEDICINE | 2,256 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 05.10.2026 | The following instruments on XETRA do have their first trading 05.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.10.2026
Aktien
1 US16934F1030 Chilwa Minerals Ltd.... ► Artikel lesen |
Das Unternehmen CNS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,340 Euro und damit +2,10 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.